Trial Profile
An Open Label Pharmacokinetic and Efficacy Study of 0.5 μg/Day and 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts in Subjects With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacokinetics
- Sponsors Alimera Sciences
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
- 31 Jan 2012 Actual end date (1 Apr 2011 ) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov